Olmesartan Medoxomil Accord

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Accord, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to treat hypertension in adults. GNH USA supplies Olmesartan Medoxil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil is an angiotensin II receptor blocker indicated for several cardiovascular conditions.

- Hypertension: lowers blood pressure and reduces the risk of cardiovascular events. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: helps protect kidney function by controlling blood pressure. - Post‑myocardial infarction: assists in long‑term blood pressure management after a heart attack. - Stroke prevention: contributes to secondary prevention of ischemic stroke in high‑risk patients. - Chronic kidney disease: aids in slowing disease progression when hypertension is present.

Olmesartan Medoxil Accord may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Cough

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Allergic skin reactions

When prescribing Olmesartan Medoxil Accord, clinicians should consider several safety aspects.

- Renal function monitoring: assess baseline kidney function and adjust as needed. - Electrolyte balance: watch for hyperkalemia, especially with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Hypotension risk: caution in patients with volume depletion or on other antihypertensives. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil Accord can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes or renal impairment) - Potassium‑supplement containing products - Lithium (may increase serum lithium levels)

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (may reduce antihypertensive effect) - Diuretics (enhance hypotensive response) - ACE inhibitors or other ARBs (risk of additive renal effects) - Cyclosporine (may increase olmesone levels)